A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
A phase 3 trial of Trastuzumab rezetecan and Trastuzumab emtansine in HER2-positive breast cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.
Overview
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy is a phase 3 interventional study registered as NCT06126640 by Jiangsu HengRui Medicine Co., Ltd., with 1615 participants enrolled, started 2023-11-20 and due to reach its primary completion in 2030-04. Interventions recorded: SHR-A1811 and Trastuzumab Emtansine.
Similar pages
not linked directly; found by shared links- TrialA Study of SHR-4610 Injection in Patients With Advanced Solid Tumors
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialPhase II Clinical Study of SHR-A1811 in Patients With HER2 Expression / Amplification of Locally Advanced Unresectable or Recurrent Metastatic Biliary Tract Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, HER2-positive breast cancer and the tag pipeline.
- TrialA Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialSafety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialSHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.
- TrialA Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals and the tag pipeline.